Science at Sanofi

We are pleased to share with you information on ‘Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis,’ together with the ‘Guidelines of Care for the Management of Atopic Dermatitis in Pediatric Patients.’ We believe these publications may be of interest to you.

This email highlights key evidence regarding dupilumab, including its long-term safety and efficacy profile in infants and young children with atopic dermatitis. It also presents current guideline recommendations, which strongly support the use of dupilumab in children aged 6 months and older with moderate-to-severe atopic dermatitis.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated June evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children

I am pleased to share information regarding the Biologics in Atopic Dermatitis: Effectiveness, Safety, and Future Directions, which you may find of interest. In this email, you will find the key highlights on dupilumab for long-term disease management in atopic dermatitis.

SCORE-AD Calculator & Atopic Dermatitis Assessment Tools for Healthcare Professionals. Access validated severity scales including SCORAD, EASI, vIGA-AD, DLQI, and POEM to evaluate disease severity, patient outcomes, and quality of life in one platform.

แนวทางกำกับการเบิกจ่ายค่ายา Dupilumab ข้อบ่งใช้ โรคผื่นภูมิแพ้ผิวหนัง (Atopic dermatitis) สำหรับผู้ป่วยเด็กที่มีอายุตั้งแต่ 6 เดือน ถึง 12 ปี

แนวทางการจ่ายยา dupilumab ในรักษาโรคหืดรุนแรง

Explore ATS 2026 key sessions on dupilumab, COPD biologics, FeNO biomarkers, and asthma remission. Real-world evidence for HCPs

The United in Rare: Advancing LSDs Care across Asia event was held on the 22^nd to 23^rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Access the full recording of the webinar to gain insights on Atopic Dermatitis, Bullous Pemphigoid, and practical applications from leading experts.

Discover the latest breakthroughs in pediatric infectious diseases, focusing on Pertussis, Polio and Hib protection.

Explore key clinical insights and trial data from ERS 2025, including breakthroughs in biologics for asthma and COPD, pediatric asthma management, and AI-enabled respiratory innovation. Curated for healthcare professionals.

Explore the latest scientific insights and clinical updates from the European Academy of Dermatology and Venereology (EADV) 2025 Congress held in Paris. This year’s sessions spotlighted transformative developments in the management of atopic dermatitis (AD), chronic spontaneous urticaria (CSU), and bullous pemphigoid, with a strong focus on real-world evidence, emerging biologics, and the role of artificial intelligence in dermatology.

T2D patients with uncontrolled on Basal insulin switching to iGlarLixi

T2D patients with uncontrolled on Premixed insulin

Uncontrolled on GLP-1 RA:​ 
What’s the next step?​
by Assoc. Prof. Taweesak Wannachalee

When OADs are not enough: Choosing Gla-300 for stability by Dr. Kampantong Tangweerapong

T2D patients with post-OADs, high A1C and PPG by Dr. Chonpiti Siriwan

LMWH in Acute Coronary Syndromes by DR.PURICH SURUNCHUPAKORN.

Watch now to gain clinical insights from Dr. Wiwat Rodprasert

Don’t wait—see how early treatment changes outcomes.